Decoy Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
One Broadway 14th Floor, Cambridge, Mass...Phone Number
(713) 913-5608Website
www.decoytx.comRevenue
-Stock Symbol
DCOYIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Decoy Therapeutics
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology.Explore more
Decoy Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Decoy Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Decoy Therapeutics is spiking on competitors!
Decoy Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Decoy Therapeutics recently announced quarterly report
Click to see if Decoy Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Decoy Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Decoy Therapeutics
Website visits: Recent activity has been detected on your website
Check if Decoy Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Decoy Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Decoy Therapeutics as Masked Content
Find 2 more new buyers
Decoy Therapeutics financials insights
Gather financial insights about Decoy Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Debt
$1.2M
2026
Stock/Share Issuance
$3.5M
Decoy Therapeutics Tech Stack
A closer look at the technologies used by Decoy Therapeutics
Most Recent Scoops
Funding
Decoy Therapeutics has secured $3.5 million in Stock Issuance funding. Investors were not disclosed.
Funding
Funding
, according to a recent Form D filing, has secured $1,200,000 in Debt funding.
Funding
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Lateral Move
Executive Move
Executive Moves, Lateral Move
Lateral Move
Executive Move
Executive Moves, Lateral Move
Decoy Therapeutics News & Media
Decoy Therapeutics Enters Up To $21 Mln PIPE Financing; Stock Surges In Pre-Market
Decoy Therapeutics, Inc. (DCOY), a clinical-stage biotech company, announced it entered into a securities purchase agreement with a single healthcare-focused institutional investor for a private investment in public equity (PIPE).Decoy Therapeutics (NASDAQ: DCOY) lines up $21M milestone-based PIPE funding
Decoy Therapeutics arranges a PIPE with $3.5M upfront and up to $17.5M in milestone warrant proceeds to fund its multi-viral antiviral programs toward clinical trials.Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families,...Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
CAMBRIDGE, Mass., June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced the nomination of Patricia Gauthier,...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Decoy Therapeutics
Sign Up For FreeTo access detailed company insights
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and... Read More
